YMAB Y-mAbs Therapeutics Price-to-Projected Revenue Ratio
The reliability of pediatric drug delivery via strict temperature control ensures the stability of Y-mAbs Therapeutics (YMAB) supply chains. The company's forward P/S serves as an indicator of investor confidence, where 4.60 indicates the current level of the metric. The business adheres to bioethics in testing and eco-friendly waste disposal, while regular sales of approved drugs support the cash flow for new research.
Analytical breakdowns for Y-mAbs Therapeutics
- stock price and consensus target price:
- market capitalization data:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Y-mAbs Therapeutics|YMAB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Y-mAbs Therapeutics|YMAB - Aggregate Debt Obligations|Debt to Book Value Y-mAbs Corp|YMAB - Amount of Long-Term Liabilities|Company Short-Term Debts Y-mAbs Therapeutics|Quick Ratio ymabs.com
- financial results and valuation multiples details:
YMAB - Company Net Income|Expected Profit Y-mAbs Therapeutics|YMAB - Company Value to Net Income|Forward P/E Multiple YmAbs|YMAB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Corp|YMAB - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Y-mAbs Therapeutics|YMAB - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ymabs.com|YMAB - Earnings growth in current year|Expected earnings per share growth for next year Y-mAbs Therapeutics
- total revenue and sales volume data:
Summary company analysis:Y-mAbs Therapeutics, Inc. (YMAB)
Institutional capital assesses the attractiveness of Y-mAbs Therapeutics (YMAB) through the lens of expected cash flows from the commercialization of orphan drugs and the development of its oncology pipeline. By analyzing the forward P/S trend, which compares the current market value of the business to projected revenue, investors determine the degree of asset overvaluation and the reliability of its fundamental value relative to the risks of new therapy approvals.
Competing companies
BeiGene - Forward Price-to-Revenue Multiple|Projected Price to Revenue Halozyme Therapeutics, Inc.|RVMD - Price-to-Projected Revenue Ratio|Ascentage Pharma Corp (AAPG) - Forward Price-to-Revenue Multiple|CGON: Forward P/S Multiple|urogen.com (URGN) - Forward P/S Multiple|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|Market Cap to Expected Sales Ratio Delcath Corp|Aura Biosciences, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|SELLAS Life Sciences - Price to Expected Revenue Ratio|ACTU: Forward P/S Multiple|Citius Oncology Inc - Forward Price to Sales|HURA (TuHURA Biosciences Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio protaratx.com TARA|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|WHWK (aadibio.com) - Forward Price to Sales|Forward P/S Multiple TCRX (TScan Therapeutics, Inc.)|Forward P/S Multiple Champions Oncology Inc CSBR|XBIT - Price-to-Projected Revenue Ratio|Future Price to Revenue CVM|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio radiopharmtheranostics.com (RADX)|Forward Price-to-Revenue Multiple ARTV|Forward P/S Multiple Adlai Nortye Limited|Forward Price-to-Revenue Multiple VERU (Veru Inc.)|Price to Expected Revenue Ratio TPST|Forward P/S Multiple XLO (Xilio Therapeutics)|Market Cap to Expected Sales Ratio Renovaro Biosciences (RENB)|Mural Bio - Forward P/S Multiple|Kairos Pharma Ltd (KAPA) - Forward Price-to-Revenue Multiple|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|GDTC - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CRIS|Market Cap to Future Revenue Ratio Apollomics Corp APLM|Price-to-Projected Revenue Ratio Tharimmune Corp (THAR)|Forward Price-to-Revenue Multiple advanbiomed.com ADVB|Forward P/S Multiple GNPX (Genprex, Inc.)|Forward P/S Multiple Calidi Biotherapeutics Inc. CLDI|Sunshine Biopharma, Inc. - Forward P/S Multiple|XBIO: Price-to-Projected Revenue Ratio|SLRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Kitov Pharma|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward P/S Multiple beigene.com|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Market Cap to Projected Revenue|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|Notable Labs, Ltd. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Viracta Therapeutics|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Inc - Forward Price to Sales|Forward Price-to-Revenue Multiple AAPGV
